Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b Multicenter, Single Dose, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates

NCT01887327 is registered in ClinicalTrials.gov with InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company as lead sponsor.

NCT NCT01887327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01887327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b Multicenter, Single Dose, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of Two Doses of Stannsoporfin in Combination With Phototherapy in Neonates
Lead sponsor
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company
Phase
Phase 2
Overall status
Completed
Start date
October 16, 2013
Completion date
March 22, 2016
Enrollment
91 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hyperbilirubinemia, neonatal, jaundice, neonatal